### Spironolactone

**Section:** 16. Diuretics

<table>
<thead>
<tr>
<th>Indication</th>
<th>Ascites</th>
<th>ICD11 code: ME04</th>
</tr>
</thead>
<tbody>
<tr>
<td>INN</td>
<td>Spironolactone</td>
<td></td>
</tr>
<tr>
<td>Medicine type</td>
<td>Chemical agent</td>
<td></td>
</tr>
<tr>
<td>List type</td>
<td>Core (EML) Complementary (EMLc)</td>
<td></td>
</tr>
</tbody>
</table>
| Formulations | Oral > Liquid: 10 mg per 5 mL (EMLc); 25 mg per 5 mL (EMLc); 5 mg per 5 mL (EMLc)  
Oral > Solid: 25 mg |
| EML status history | First added in 1977 (TRS 615)  
Removed in 1979 (TRS 641)  
Added in 1982 (TRS 685)  
Changed in 1987 (TRS 770)  
Changed in 1997 (TRS 882)  
Changed in 2007 (TRS 950)  
Changed in 2009 (TRS 958) |
| Sex        | All |
| Age        | Also recommended for children |
| Therapeutic alternatives | The recommendation is for this specific medicine |
| Patent information | Patents have expired in most jurisdictions  
Read more about patents. |

**Wikipedia**  
Spironolactone

**DrugBank**  
Spironolactone

---

**Summary of evidence and Expert Committee recommendations**

The EMLc Subcommittee recommended the strengths of spironolactone oral liquid be changed from 1-20 mg/mL to 5 mg/5mL, 10mg/5mL and 25 mg/5 mL.